Cyberonics Seeks Suitor To Transform Into Premier Neuromodulation Firm
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics' aim to become the global neuromodulation leader following FDA approval of its VNS Therapy for treatment-resistant depression could depend on its attractiveness as an acquisition target
You may also be interested in...
Cyberonics investors take profits
Advanced Neuromodulation Systems divests 3.5 mil.-share, 15% equity stake in Cyberonics via open market transactions Feb. 14-17, according to SEC filings. ANS had purchased the shares last summer as part of a failed attempt to acquire the company. Cyberonics CEO Skip Cummins also sheds 23% of his holdings (350,000 Cyberonics shares), citing the recent opening of the firm's insider trading window Feb. 10. The exec sold an additional 18,000 shares the following day. Cyberonics stock has gained more than 50% in the wake of a Feb. 2 FDA "approvable" letter for VNS Therapy depression treatment (1"The Gray Sheet" Feb. 7, 2005, p. 4)...
Cyberonics investors take profits
Advanced Neuromodulation Systems divests 3.5 mil.-share, 15% equity stake in Cyberonics via open market transactions Feb. 14-17, according to SEC filings. ANS had purchased the shares last summer as part of a failed attempt to acquire the company. Cyberonics CEO Skip Cummins also sheds 23% of his holdings (350,000 Cyberonics shares), citing the recent opening of the firm's insider trading window Feb. 10. The exec sold an additional 18,000 shares the following day. Cyberonics stock has gained more than 50% in the wake of a Feb. 2 FDA "approvable" letter for VNS Therapy depression treatment (1"The Gray Sheet" Feb. 7, 2005, p. 4)...
Cyberonics Depression Approval Contingent On Dosing Trial, Registry
Cyberonics will start a 450-patient, three-year dosing trial in order to gain PMA approval for its VNS Therapy neuromodulation device for use in treatment-resistant depression patients